The Dow Jones Industrial Average, S&P 500 and Nasdaq Composite all ended in the green Monday for St. Patrick's Day, rising for a second straight session as markets continued to partially rebound from their recent tariff-induced sell-off.
The $Dow Jones Industrial Average (.DJI.US)$ led the way higher, gaining 353.45 points (0.9%) to end the day at 41.841.63. The $S&P 500 Index (.SPX.US)$ likewise added 3...

$Incyte (INCY.US)$
Breakthrough: Dual Phase 3 Trials Prove Povorcitinib's Success in Treating Hidradenitis Suppurativa

$Incyte (INCY.US)$
Can Incyte's Opzelura Break Through in Prurigo Nodularis? Phase 3 Data Reveals Critical Insights

$Incyte (INCY.US)$
Can Incyte's New Clinical Data Revolutionize Prurigo Nodularis Treatment? AAD 2025 Reveals Answers

$Incyte (INCY.US)$
AI Meets Drug Discovery: Inside Incyte's $620M Genesis Deal - Will This Transform Pharma R&D?

$Incyte (INCY.US)$ $Agenus (AGEN.US)$ Reuters· 2 mins ago
Agenus Inc - Incyte to Terminate Agreement With Agenus Effective February 2026

$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.

Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide) 
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...